Cancer Research UK has awarded nearly £60 million in funding to three US investigator-led research initiatives focused on cancer progression and drug response.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.
The company believes it can provide tests to predict patients' responsiveness to specific drugs akin to the molecular diagnostics that have now swelled the oncology space.
In a colon cancer model, researchers saw transcriptional changes and population expansions in some checkpoint receptor-negative tumor-infiltrating T cells.
BabySeq Project researchers reported that genomic sequencing could find even healthy newborns who are at risk of developing childhood-onset conditions.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.
In PNAS this week: artemisinin resistance mutations in malaria parasites, ant-plant interactions over time, and more.
Three studies encompassing dozens of ancient genomes are offering a closer look at complex historical population spread in North, Central, and South America.
23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.
He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.
Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.
In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.